Isaac Ciechanover, MD Founder, President, & CEO
|
|
- Christine Charles
- 5 years ago
- Views:
Transcription
1 Isaac Ciechanover, MD Founder, President, & CEO Jefferies Global Healthcare Conference June 3, 2015 Proprietary Materials
2 Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, collaborations, regulatory approvals, the possible impact of accelerated approval and whether the receipt of breakthrough therapy designation will meaningfully impact review by the U.S. Food and Drug Administration or the likelihood that a product will be found to be safe and effective, our ability to sell, manufacture or otherwise commercialize our product candidates, research and development costs, the timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, and our ability to obtain and maintain intellectual property protection for our product candidates, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important risk factors are described more fully in documents filed by Atara with the Securities and Exchange Commission (SEC), including Atara s annual report on Form 10-K for the year ended December 31, Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Atara's own internal estimates and research. While Atara believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Atara s internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. The content of this presentation is subject to copyright, which will be asserted by Atara and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Atara. 2
3 Foundation Built on World-Class Science Sep 2012 License Sep 2014 Option TGF-β family protein modulators Seven product candidates Clinical Stage Programs T-cell immunotherapies Platform to develop additional product candidates PINTA 745 Ph 2 STM 434 Ph 1 T-cell EBV¹ Ph 2 T-cell CMV² Ph 2 T-cell WT1³ Ph 1 ¹ EBV = Epstein-Barr virus ² CMV = cytomegalovirus ³ WT1 = Wilms tumor 1 3
4 PINTA 745 PINTA 745 Protein-Energy Wasting in End-Stage Renal Disease (ESRD) 4
5 PINTA 745: Potential First in Class Molecule for PEW Phase 2 Program with Established Proof of Concept (POC) PINTA 745 Blocks myostatin, preventing it from inhibiting muscle production Improved lean body mass, physical function, inflammation in CKD¹ model Statistically significantly increased lean body mass and lower extremity muscle size in randomized, blinded Phase 1 study in prostate cancer; acceptable safety Attractive Market PEW state of muscle wasting, inflammation, malnutrition in ESRD; no approved therapies Decreased physical function, increased morbidity and mortality ~250K patients in US² and 800K worldwide Upcoming Milestone Randomized, blinded, placebo controlled Phase 2 trial (48 PEW patients) Phase 2 data expected in 4Q:15 ¹ CKD = chronic kidney disease ² Calculated utilizing 2011 data from USRDS extrapolated to December 31, 2013 as well as data from the recent study completed with DaVita Clinical Research 5
6 Clinical POC in Patients with Prostate Cancer Receiving ADT¹ PINTA 745 Lean Body Mass Increase Lower Extremity Muscle Size Increase 8% N = % N = % 10% % of Baseline 4% 2% 0% (2)% (4)% % of Baseline 8% 6% 4% 2% 0% (2)% (4)% P=0.065 P=0.007 (6)% (6)% EOS FUP 3.0 mg/kg PINTA 745 Placebo 3.0 mg/kg PINTA 745 Placebo ~2% greater in lean body mass at EOS Difference in lean body mass compared to placebo continued to increase in 4 weeks after treatment (FUP) At EOS, muscle size increased by ~1.2% from baseline At FUP, the change from baseline increased to 2.7% Source: Padhi et al., Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 99(10):E1967 Note: The bottom and top of the boxes represent the first and third quartiles, and the horizontal band inside the box indicates the median value. The ends of the whiskers represent the minimum and maximum data in the range of observations Note: EOS: end-of-study (at day 29); FUP: Follow-up Period (one month after day 29) ¹ ADT = androgen deprivation therapy 6
7 Increased Mortality in Patients with PEW PINTA 745 Survival Rates Based Upon Serum Albumin Levels 100% 80% Percentage Surviving 60% 40% 20% Results at one year: ~11% of PEW¹ patients died within one year compared to < 3% of non- PEW patients At three years: ~40% of PEW patients died in comparison with ~21% of non-pew patients 0% Days from Entry into Database Serum Albumin 3.8 g/dl Serum Albumin > 3.8 g/dl 54% of dialysis patients suffer from PEW 1 Large unmet need; ~250,000 2 US; ~800,000 Worldwide 1 Based on a recent study we completed with DaVita Clinical Research, a division of DaVita Healthcare Partners Inc. 2 Calculated utilizing 2011 data from USRDS extrapolated to December 31, 2013 as well as data from the recent study completed with DaVita Clinical Research 7
8 Preclinical Proof of Concept in CKD Mice PINTA 745 Ctrl CKD Received from William E. Mitch, Baylor College of Medicine, M.D. Myostatin is Over-Expressed in CKD Mice and PINTA 745/s Has a Demonstrated Ability to Increase Body Weight ¹ Synthesis (nmol Phe/g/hr) * * P<0.05 Placebo PINTA 745/s Degradation (nmol Tyr/g/hr) Placebo * P<0.05 * PINTA 745/s pg / ml TNF - α IL - 6 P=0.033* P=0.036* Placebo PINTA 745/s Placebo PINTA 745/s pg / ml Increase Protein Synthesis ¹ Limit Protein Degradation ¹ ¹ Based on a preclinical study conducted with Amgen (Zhang L & Mitch WE, FASEB J. 2011) and Reduce Inflammation¹ 8
9 Ongoing Phase 2 Trial in ESRD Patients with PEW Phase 2 Data Expected 4Q:15 PINTA 745 Randomized, double-blind, placebo-controlled trial in 48 patients Primary endpoint change in muscle mass Secondary endpoints physical function, monitoring of inflammatory markers, effects on use of supportive care drugs, QOL¹ assessments Clinical Update Phase 2 Trial in ESRD Patients with PEW No treatment-related serious adverse events, grade 3 adverse events Initial regimen safe and well tolerated Study enrollment ongoing ¹ QOL = Quality of Life 9
10 MSK Collaboration 10
11 Atara MSK Collaboration Overview Pathway to Commercialization Sponsored Research Ongoing and Planned POC Studies Allogeneic, cellular therapy platform technology developed by MSK Exclusive Option to license 3 clinical T-cell programs targeting some viral or cancer antigens Collaborate on further research to discover additional cellular therapies Leverage existing technology to target other antigens Develop additional cellular therapies and / or CAR-T cell programs 11
12 Platform Attributes Off-the shelf cellular therapeutic option for patients EBV - CTLs Manufacturing process designed to reduce risk of product-related GvHD¹ MSK has developed libraries of EBV, CMV, and WT1 activated cell lines MANUFACTURE 1 T-cells from Donor Blood 2 Antigen exposure, expansion and characterization 3 Targeted T- cell Banks THERAPEUTIC USE Cancer or Viral Infection Blood Test: HLA² Typing Off-the-shelf T-cell Doses 1 GvHD = graft versus host disease ² HLA = human Leukocyte Antigen 12
13 Targeted T-Cell Therapy for EBV-LPD after HCT Current Treatment Approach EBV - CTLs If Rituximab Failure EBV Reactivation: Lymphoma EBV-LPD Standard Rx: e.g., Rituximab Rituximab (anti-cd20 Ab) is often used off-label as 1 st line therapy; Off-the-shelf EBV-Targeted T-cell Doses Historical survival in rituximab refractory patients median days 1 Time Course of a Complete Response Following Administration of EBV Targeted T-cell 2 ¹ Prockop, S et al., Proc AACR (2015), Fox 2014, Ocheni 2008, Uhlin MSK Data on file 13
14 Clinical Experience with EBV-CTL in EBV-LPD EBV - CTLs Two separate clinical trials of EBV-CTL conducted by MSK Study Primary HCT and 3 rd party donor derived EBV-CTL Study rd party donor derived EBV-CTL Includes EBV-LPD after HCT and solid organ transplant (SOT) Results in EBV-LPD after HCT presented in a Clinical Trials Plenary session at AACR 2015 (April 19, 2015) Results in EBV-LPD after SOT presented at ASCO 2015 (June 1, 2015) 14
15 Clinical POC in EBV-LPD after HCT: Phase 2 Study Results¹ Response Rate (RR): Primary vs. 3 rd party Donor EBV-CTL Source N Prior Rituximab RR 2 DCR 2 EBV - CTLs 2015 ASCO Presentation Overall Survival: Rituximab Refractory Patients Treated with 3 rd party EBV-CTL Study Primary Donor % 69% 3 rd Party Donor % 70% 1 year OS = 71.8% 2 year OS = 63.8% N = 22 RR with primary HCT and 3rd party donor comparable RR in rituximab treated patients similar to overall RR Complete and partial responses were durable & led to the overall survival results observed Well tolerated, few serious related AEs; no cytokine release, 1 grade 1 GvHD resolved without systematic therapy Historical survival in rituximab refractory patients median days ¹ Prockop, S et al., Proc AACR (2015), Prockop, S et al., Proc ASCO (2015), Based on results from two clinical trials of EBV-CTL conducted by MSK 2 RR = complete response + partial response; DCR = Disease control rate = complete response + partial response + stable disease 3 Prockop, S et al., Proc AACR (2015) 4 Prockop, S et al., Proc ASCO (2015), Includes 22 patients from Study plus 11 patients from Study plus one patient treated under a treatment IND Study year OS = 56.3% 2 year OS = 46.9% N = 12 15
16 EBV-CTL: EBV-LPD after SOT 2nd Indication¹ EBV-CTL Source Response Rate (RR): EBV-LPD after SOT N Prior Rituximab Prior Chemo RR 2 3 rd Party Donor % Note: All patients had failed to respond or relapsed following rituximab treatment; 11 SOT recipients also progressed after 1-5 courses of rituximab and chemotherapy OS in Rituximab Refractory EBV-LPD after SOT following treatment with 3rd party EBV-CTL Results Response Rate (RR) for SOT of 62% is similar to RR for HCT 1 durable CR (>22mo) and 7 durable PRs (range: mo) in heavily pre-treated patients 12 of the 13 patients had high risk disease 3 (Age 60 years; poor performance status; elevated LDH) Overall Survival (OS) of 58% at 2 years compares favorably with historical data Historical Data 3 Historical data show 33% OS at 2 years in patients with incomplete response to rituximab Historical data show 0% OS at 2 years in patients with high risk disease ¹ Prockop, S et al., Proc ASCO (2015), Based on results from two clinical trials of EBV-CTL conducted by MSK 2 RR = complete response + partial response 3 Choquet et al.,
17 Phase 2 Clinical POC in antiviral resistant CMV after HCT¹ CMV - CTLs Current Treatment Approach If Treatment Failure or Intolerance CMV Reactivation: Viremia or Disease CMV Standard Rx: e.g., Ganciclovir or Foscarnet Off-the-shelf CMV-Targeted T-cell Doses Responses Following Administration of CMV Targeted T-cells Viremia Only 2 CMV Disease 3 25 Evaluable Patients 9 Complete Responses 7 Partial Responses 9 Evaluable Patients 5 Complete Responses 1 Partial Responses Response Rate = 64% Response Rate = 67% Interim data presented at ASH 2014; No de novo GvHD or flare of pre-existing GvHD was noted ¹ Prockop, S et al., Proc ASH (2014), MSK (data on file) 2 Responses in patients treated for viremia alone were considered complete if the viremia resolved completely and partial if it fell by more than 100-fold 3 Responses in disease were considered complete if all detectable CMV viremia and disease resolved and partial if patients became asymptomatic 17
18 STM 434 STM 434 Ovarian Cancer and Other Solid Tumors 18
19 STM 434: Potential First in Class Molecule for Ovarian Cancer and Other Solid Tumors STM 434 Phase 1 Program with Pre-clinical POC Inhibits Activin A, which is involved in proliferation of OC and other solid tumor Reduced tumor size as single agent and with chemotherapy preclinically Demonstrated efficacy in granulosa / clear cell preclinical models of OC Gene mutations in FOXL2 and ARID1A link Activin to granulosa and clear cell OC, respectively Attractive Market Opportunity for rapid development in difficult-to-treat clear and granulosa cell OC Expansion opportunities in serous OC and other solid tumors ~22K new OC cases in 2013 in the US 1 Upcoming Milestone 3 part Phase 1 ongoing including dose escalation, dose expansion, chemo combo Initial Phase 1 data expected 1H:16 ¹ National Cancer Institute estimate 19
20 Pre-clinical POC in Granulosa Cell Ovarian Tumors STM 434 Suppressed Tumor Growth Improvement in Survival 1 Normal Control Treated with Placebo Ovarian Tumor Size Inhibin Knockout Treated with Placebo Inhibin Knockout Treated with STM 434/s Right Left FOXL2 granulosa cell tumor gene linkage 2 In normal cells, FOXL2 protein turns on follistatin when activin signal received; shuts off activin signal In granulosa cell OC, mutant FOXL2 is not able to turn on follistatin; activin signals unchecked Mutation was present in 97% of granulosa cell tumors ¹ Zhou X, et al. Cell. 2010; 142(4): Shah S. P., et al. NEJM. 2009; 360:
21 Pre-clinical POC in Clear Cell Ovarian Tumors STM 434 Significant Reduction in Tumor Volume¹ Enhanced Body Weight¹ ARID1A clear cell tumor gene linkage 2 ARID1A mutations drive upregulation in signaling cascade triggered by ActR2B receptor Mutations present in 46%-55% of ovarian clear cell tumors Increased activin levels, like ARID1A mutations, may contribute to clear cell tumor proliferation ¹ Lu J, Haqq C, & Han HQ. ASCO Annual Meeting (2013) 2 Wiegard., et al. NEJM. 2010; 363:
22 Ongoing First-in-Human (Phase 1) Study First Patient Dosed 10/14; Initial Data Readout Expected 1H:16 STM 434 Dose Escalation in Solid Tumors Monotherapy Dose Expansion in OC Combo Chemotherapy in OC Three part open-label Phase 1 study in up to 66 patients Objectives include: Evaluate whether STM 434 is safe and well tolerated Obtain preliminary efficacy data in ovarian cancer and other solid tumors Explore biomarkers predictive of response to treatment Define recommended Phase 2 dose 22
23 Multiple Opportunities for Value Creation Validated Clinical Programs Attractive Markets PINTA 745: Myostatin inhibitor for protein-energy wasting (PEW) MSK T-Cell Programs: Option to license T-cell platform technology with 3 clinical stage, off-the-shelf, immune therapies; Breakthrough Therapy Designation granted in February 2015 for EBV-CTL in patients with EBV-LPD STM 434: Activin inhibitor for ovarian cancer and solid tumors PEW: Increased morbidity / mortality; ~250K patients in the US¹ and 800K worldwide; no approved therapeutics EBV-LPD (~1200 patients in US + EU³) and anti-viral drug resistant CMV viremia or disease (~1100 patients in US + EU 4 ); potentially rapid path to approval Ovarian Cancer (OC): One of the deadliest cancers in women in the US; ~22K new cases in 2013 in the US 2 ; expansion opportunities in other solid tumors Upcoming Milestones PINTA 745: Phase 2 data in 4Q:15 EBV-CTL: Data presented at AACR Clinical Trials Plenary April 19, 2015 Oral presentation at ASCO June 1, 2015 MSK T-cell Programs: Data submitted to multiple conferences in 2015 STM 434: Phase 1 data in 1H:16 ¹ Calculated utilizing 2011 data from USRDS extrapolated to December 31, 2013 as well as data from the recent study completed with DaVita Clinical Research ² National Cancer Institute estimate ³ Atara estimate based on the CIBMTR reports of number of HCT in the US in 2011 and a report in the journal Haematologica (2013) 4 Atara estimate based on investigator experience 23
24 June 2015
Cowen Healthcare Conference
Ola EBV+ PTLD survivor Cowen Healthcare Conference March 12, 2019 Isaac Ciechanover, M.D. Chief Executive Officer & President Nasdaq: ATRA 1 Forward-Looking Statements This presentation and the accompanying
More informationInvestor Presentation
Investor Presentation September 12, 2018 Nasdaq: ATRA Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationForward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationFirst self-administered antibody therapy for HIV in late-stage clinical trials. CytoDyn Annual Meeting of Stockholders August 24, 2017
First self-administered antibody therapy for HIV in late-stage clinical trials CytoDyn Annual Meeting of Stockholders August 24, 2017 (OTCQB: CYDY) www.cytodyn.com Forward-Looking Statements This presentation
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO
NASDAQ: DRNA Corporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO Forward looking statements This information may contain projections
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationEFFICACY AND SAFETY OF TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED LEIOMYOSARCOMAS (EBV + LMS)
EFFICACY AND SAFETY OF TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED LEIOMYOSARCOMAS (EBV + LMS) Lauren S. Kurlander, 1 Ashok Srinivasan, 2 Armin Ghobadi, 3 Stephanie Suser, 4 Ekaterina
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More information1Q2018 EARNINGS CALL MAY 7, 2018
1Q2018 EARNINGS CALL MAY 7, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCompany Presentation. September 2018
Company Presentation September 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationBringing Breakthrough Pioneering Therapies to Patients with Life-Threatening Diseases. Corporate Presentation. January 2018
Bringing Breakthrough Pioneering Therapies to Patients with Life-Threatening Diseases Corporate Presentation January 2018 Disclaimer In addition to historical facts or statements of current condition,
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationProgrammed Cellular Immunotherapies
Better Cells For Better Therapies Programmed Cellular Immunotherapies Corporate Overview August 2017-1 - Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationATA129 for Epstein-Barr virusassociated. lymphoproliferative disorder
March 2017 Horizon Scanning Research & Intelligence Centre ATA129 for Epstein-Barr virusassociated post-transplant lymphoproliferative disorder NIHR HSRIC ID: 10876 Lay summary ATA129 is a new treatment
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationDEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS
DEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS February 22, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More information